850p 0.5 0.1%
Last Trade - 16/04/21
| Market Cap | £1.13bn |
| Enterprise Value | £1.48bn |
| Revenue | £518.7m |
| Position in Universe | 412th / 1819 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 184.4 | 339.9 | 302.3 | 381.2 | 456.9 | 504.3 | 538.9 | 651.8 | +22.3% | ||
| +36.9 | +1.5 | +1.9 | +17.7 | +12.1 | +0.2 | +55.3 | +20.6 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 12, 2008 |
| Public Since | September 25, 2012 |
| No. of Shareholders: | n/a |
| No. of Employees: | 25 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 133,029,000 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Pitcairn House,Crown Square First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom |
| Web | http://www.clinigengroup.com/ |
| Phone | +44 1283 495010 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 16/04/21, shares in Clinigen are trading at 850p, giving the company a market capitalisation of £1.13bn. This share price information is delayed by 15 minutes.
Shares in Clinigen are currently trading at 850p and the price has moved by 37.65% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Clinigen price has moved by 10.09% over the past year.
Of the analysts with advisory recommendations for Clinigen, there are there are currently 4 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Clinigen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Clinigen is scheduled to issue upcoming financial results on the following dates:
The Clinigen dividend yield is 0.9% based on the trailing twelve month period.
Last year, Clinigen paid a total dividend of 0.08, and it currently has a trailing dividend yield of 0.9%. Looking ahead, Clinigen has not announced an ex-dividend date yet.
Clinigen has yet to annouce their ex-dividend date. The historic dividend yield on Clinigen shares is currently 0.9%.
To buy shares in Clinigen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Clinigen are currently trading at 850p, giving the company a market capitalisation of £1.13bn.
Here are the trading details for Clinigen:
Based on an overall assessment of its quality, value and momentum, Clinigen is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Clinigen are currently priced at 850p. At that level they are trading at 24.29% discount to the analyst consensus target price of 1,122.71.
Analysts covering Clinigen currently have a consensus Earnings Per Share (EPS) forecast of 0.62732 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clinigen. Over the past six months, the relative strength of its shares against the market has been 11.76%. At the current price of 850p, shares in Clinigen are trading at 21.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Clinigen PE ratio based on its reported earnings over the past 12 months is 22.43. The shares are currently trading at 850p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Clinigen's management team is headed by:
Here are the top five shareholders of Clinigen based on the size of their shareholding:
